We studied the penetration of etravirine and HIV shedding in the genital tract among 12 HIV-1-infected women receiving an etravirine-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA. None of the cervicovaginal fluid (CVF) samples showed detectable HIV RNA. Median etravirine concentrations were 663 ng/ml in BP and 857 ng/ml in CVF, with a CVF/BP etravirine ratio of approximately 1.2. This good penetration of etravirine may contribute to the control of viral replication in the female genital tract. Copyright © 2012, American Society for Microbiology. All Rights Reserved.
CITATION STYLE
Clavel, C., Peytavin, G., Tubiana, R., Soulié, C., Courbon, E., Crenn-Hebert, C., … Mandelbrot, L. (2012). Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study. Antimicrobial Agents and Chemotherapy, 56(7), 4018–4020. https://doi.org/10.1128/AAC.06474-11
Mendeley helps you to discover research relevant for your work.